ISRCTN41486350已完成不适用

A randomised study of Gemcitabine with Carboplatin versus Mitomycin, Vinblastine and Cisplatin (MVP) or Mitomycin C, Ifosfamide and Cisplatin (MIC) chemotherapy in inoperable advanced stage non-small cell lung cancer (NSCLC)

Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)0 个研究点目标入组 372 人开始时间: 2003年9月12日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. NHS patients with pathologically confirmed NSCLC, stage IIIa, IIIb, or IV
•2. ineligible for curative radical radiotherapy or surgery after discussion in a multidisciplinary team setting comprised of at least a chest physician, a surgeon, and an oncologist
•3. no previous chemotherapy
•4. age older than 18 years
•5. life expectancy of at least 12 weeks
•6. adequate bone marrow reserve (leukocyte count > 3 × 10^9/L, platelet count > 100 × 10^9/L, and hemoglobin > 100 g/dL)
•7. creatinine clearance > 60 mL/minute
•8. adequate birth-control measures

•1. active infection
•2. bony disease as the only measurable disease
•3. prior radiotherapy to the sole site of assessable disease
•4. inadequate renal or hepatic function
•5. serious comorbidity
•6. other malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)
•7. peripheral neuropathy Grade > 2
•8. significant neurologic or psychiatric disorder
•9. symptomatic brain metastases

发起方

Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)